TY - GEN AU - Grégoire Ruffenach AU - Jason Hong AU - Mylène Vaillancourt AU - Lejla Medzikovic AU - Mansoureh Eghbali TI - Pulmonary hypertension secondary to pulmonary fibrosis: clinical data, histopathology and molecular insights. PY - 2020/// CY - [Place of publication not identified] PB - BMC KW - Pulmonary fibrosis KW - Pulmonary hypertension KW - Vascular diseases KW - B. Sc. Medical Laboratory Science KW - UMUN open access collection KW - histopathology KW - Review articles N1 - Publication type: Review article; Linked open-access copy: published version; Open access; no subscription required for the linked open-access version N2 - Pulmonary hypertension (PH) developing secondarily in pulmonary fibrosis (PF) patients (PF-PH) is a frequent co-morbidity. The high prevalence of PH in PF patients is very concerning since the presence of PH is a strong predictor of mortality in PF patients. Until recently, PH was thought to arise solely from fibrotic destruction of the lung parenchyma, leading to hypoxic vasoconstriction and loss of vascular bed density. Thus, potential cellular and molecular dysregulation of vascular remodeling as a driver of PF-PH has been under-investigated. The recent demonstrations that there is no correlation between the severity of the fibrosis and development of PH, along with the finding that significant vascular histological and molecular differences exist between patients with and without PH have shifted the etiological paradigm of PF-PH. This review aims to provide a comprehensive translational overview of PH in PF patients from clinical diagnosis and outcome to the latest understanding of the histology and molecular pathophysiology of PF-PH UR - https://europepmc.org/articles/PMC7677848 ER -